Shukaib Arslan, MD
Hematology & Oncology · Duarte, CANPI 1477867877
Payments from drug & device makers
Across 28 payments — averaging $46,516 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$835K
- AstraZeneca$246K
- Genentech, Inc.$145K
- National Marrow Donor Program$38K
- Novartis$36K
- CSL Behring$2K
- plus $76 from 2 others
What the payments were for
- Consulting fees$2,00045%
- Speaking & faculty fees$2,15048%
- Food & beverage$2897%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 6 | $834,820 |
| AstraZeneca(2 entities) | 4 | $246,471 |
| Genentech, Inc. | 6 | $145,201 |
| National Marrow Donor Program | 4 | $38,150 |
| Novartis | 3 | $35,736 |
| CSL Behring | 2 | $2,000 |
| Amgen | 2 | $57 |
| Seagen Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIRIS$150
How this compares
$1,302,454 in reported general payments places this provider in the 90th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IdhifaEnasidenib Mesylate | 14 | $428,603 |
| JakafiRuxolitinib Phosphate | 16 | $141,930 |
| ZarxioFilgrastim-Sndz | 12 | $20,284 |
| Posaconazole | 19 | $18,839 |
| Acyclovir | 61 | $800 |
| Levofloxacin | 26 | $495 |
| Potassium Chloride | 11 | $182 |
| Atorvastatin Calcium | 16 | $108 |
| Famotidine | 12 | $64 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $42 |
| Montelukast Sodium | 11 | $31 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Duarte
- Vaibhav AgrawalDuarte$5.8M
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Nicholas McAndrewLos Angeles$22.9M
- Aditya BardiaSanta Monica$22.1M
- Joseph TuscanoSacramento$20.4M
- Zev WainbergSanta Monica$19.3M
- Caitlin CostelloSan Diego$16.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.